FDA Approves Biogen LEQEMBI IQLIK Subcutaneous Starting Dose for Early Alzheimer's

The FDA approved LEQEMBI IQLIK (lecanemab-irmb) as a subcutaneous initiation dose for early Alzheimer’s disease on July 13, 2026, more than a month ahead of its extended August 24 PDUFA date. Biogen (BIIB) and Eisai can now offer at-home injections from the very first dose, making LEQEMBI the only anti-amyloid therapy worldwide with subcutaneous dosing across the entire treatment course.

The approved initiation regimen is 500 mg once weekly, delivered as two 250 mg injections via autoinjector. Each injection takes roughly 15 seconds. LEQEMBI IQLIK was already approved in August 2025 for maintenance dosing at 360 mg once weekly after 18 months of IV treatment. This new approval closes the gap, allowing patients to start and continue therapy entirely with subcutaneous injections, switch between IV and SC at any point, or remain on IV if preferred.

Biogen stock closed at $202.19 on July 24, up from a $199.33 open on the July 13 approval day, when shares jumped to a $209.03 close on heavy volume of 2.26 million shares. The stock has since pulled back amid broader market pressure but remains above pre-approval levels.

What the data showed

The FDA’s decision was supported by sub-studies from the Phase 3 Clarity AD long-term extension. Once-weekly subcutaneous administration achieved drug exposure equivalent to intravenous dosing, supporting similar clinical and biomarker benefits including amyloid plaque removal. The safety profile was generally comparable to IV administration, with ARIA rates expected to be similar between routes. Injection-related reactions were mostly localized and mild to moderate.

LEQEMBI carries a boxed warning for amyloid-related imaging abnormalities (ARIA), including brain swelling and microhemorrhages. Subcutaneous dosing does not change this risk profile.

Why this matters

The approval removes one of the biggest practical barriers to anti-amyloid therapy: the need for biweekly IV infusions at a clinic. For elderly Alzheimer’s patients and their care partners, travel to infusion centers is a significant logistical burden that has limited uptake. An autoinjector that takes 15 seconds at home could expand the addressable patient population to those who declined or discontinued IV infusions.

Eli Lilly’s competing anti-amyloid therapy, Kisunla (donanemab), is IV-only. BMO Capital Markets called the approval a “meaningful positive” for future LEQEMBI uptake, citing clear differentiation over Kisunla. Jefferies wrote that the nod “should materially improve competitiveness” by eliminating in-patient infusions, though Kisunla retains an advantage with its finite dosing duration after four initial infusions.

What to watch next

Biogen plans a U.S. launch of LEQEMBI IQLIK as an initiation dose in late August 2026. Watch for payer coverage decisions and whether at-home administration receives reimbursement support, as that will determine whether the convenience advantage translates into commercial uptake. LEQEMBI is approved in 53 countries, with the SC initiation dose currently U.S.-only.

Biogen press release | BioSpace coverage | NeurologyLive coverage